Horgan S E, Lee J P, Bunce C
Motility Service, Moorfields Eye Hospital, London, England.
J Pediatr Ophthalmol Strabismus. 1998 Jan-Feb;35(1):9-16; quiz 44-5. doi: 10.3928/0191-3913-19980101-07.
To characterize patients choosing repeated botulinum toxin injection as a treatment for their strabismus, and assess their demand for it over time (up to 8 years).
Patients who had undergone at least eight injections were identified and their clinical records analyzed for diagnosis, demographic details, and demand for toxin injections with time. To establish any predictive variables, the details for these cases were compared with those of matched controls who had undergone fewer injections. Lastly, a questionnaire was mailed to research patients' views as to the indications and preferences for regular toxin injection as a method of treatment.
Ninety-five patients were identified (34 men, 61 women; median age 37 years), of whom 35 had consecutive exotropia and 16 had secondary exotropia. Other diagnoses represented were residual and primary deviations, restrictive exotropias, and oscillopsias. A trend of fewer injections over the attendance period was seen, and the only complication observed was upper lid ptosis in 1% of injections. Cases exhibited similar demographic composition to matched controls, but were more likely to have consecutive exotropia or secondary esotropia as a diagnosis. Univariate analysis showed evidence (p < 0.001) of an association between the number of previous operations and the odds of being a case. No evidence was found that cases and controls lived at differing distances from our hospital. The questionnaire found that 71% of patients stated appearance as the prime reason for seeking treatment, and 37% stated simplicity of toxin therapy as their reason for reattendance. Twenty-six percent of the patients were disillusioned with the results of previous surgery and preferred toxin therapy as a means of controlling their symptoms.
Botulinum toxin injection is an appropriate long-term treatment for some strabismus patients who choose not to undergo further surgery. A trend toward fewer injections with time was observed, and no adverse effects were associated with long-term treatment.
对选择重复注射肉毒杆菌毒素治疗斜视的患者进行特征描述,并评估他们在一段时间内(长达8年)对该治疗方法的需求。
确定接受过至少8次注射的患者,并分析其临床记录以了解诊断、人口统计学细节以及随时间推移对毒素注射的需求。为确定任何预测变量,将这些病例的详细信息与接受注射次数较少的匹配对照组进行比较。最后,向研究对象邮寄问卷,了解他们对定期注射毒素作为一种治疗方法的适应症和偏好的看法。
共确定了95名患者(34名男性,61名女性;中位年龄37岁),其中35名患有连续性外斜视,16名患有继发性外斜视。其他诊断包括残余和原发性斜视、限制性外斜视和视振荡。在就诊期间观察到注射次数减少的趋势,唯一观察到的并发症是1%的注射出现上睑下垂。病例的人口统计学构成与匹配对照组相似,但更有可能被诊断为连续性外斜视或继发性内斜视。单因素分析显示,既往手术次数与成为病例的几率之间存在关联(p<0.001)。未发现病例组和对照组与我院距离不同的证据。问卷调查发现,71%的患者表示外观是寻求治疗的主要原因,37%的患者表示毒素治疗简单是他们再次就诊的原因。26%的患者对先前手术的结果感到失望,更喜欢毒素治疗作为控制症状的方法。
肉毒杆菌毒素注射是一些选择不接受进一步手术的斜视患者的合适长期治疗方法。观察到随着时间推移注射次数减少的趋势,且长期治疗未发现不良反应。